Kyntra Bio posts investor presentation highlighting FG-3246/FG-3180 Phase 2 program in prostate cancer

Reuters2026/08/13 20:23

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kyntra Bio highlighted Phase 2 enrollment for FG-3246 monotherapy in metastatic castration-resistant prostate cancer, paired with FG-3180 PET imaging.
Interim Phase 2 analysis targeted for 4Q 2026, aimed at selecting an optimal Phase 3 dose based on efficacy, safety, pharmacokinetics.
Roxadustat positioned as a Phase 3-ready U.S. program for anemia in lower-risk MDS with high transfusion burden, following FDA trial-design alignment.
Phase 3 initiation for roxadustat targeted for 4Q 2026; costs for an internally run study excluded from cash runway projections.
Cash runway projected into 2028; roxadustat has Orphan Drug Designation in MDS granted in December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kyntra Bio posts investor presentation highlighting FG-3246/FG-3180 Phase 2 program in prostate cancer

You may also like

Crypto prices